- van Santvoort HC, Braam HJ, Spekreijse KR, Koning NR, de Bruin PC, et al. (2014) Peritonealcarcinomatosis in t4 colorectal cancer: occurrence and risk factors. Ann SurgOncol 21: 1686-1691.
- Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015 CA Cancer J Clin 65: 5-29.
- Lochan R, White SA, Manas DM (2007) Liver resection for colorectal liver metastasis. SurgOncol 16: 33-45.
- Osada S, Imai H, Sasaki Y, Tanaka Y, Tokuyama Y, et al. (2012) Strategy for synchronous and multiple liver metastasis. Hepatogastroenterology 59: 198-203.
- Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, et al. (2010) Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am CollSurg 210: 934-941.
- Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribero D, et al. (2007) Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann SurgOncol 14: 3481-3491.
- Sakamoto Y, Fujita S, Akasu T, Nara S, Esaki M, et al. (2010) Is surgical resection justified for stage IV colorectal cancer patients having bilobar hepatic metastases?--an analysis of survival of 77 patients undergoing hepatectomy. J SurgOncol 102: 784-788.
- Chen J, Li Q, Wang C, Zhu H, Shi Y, et al. (2011) Simultaneous vs. staged resection for synchronous colorectal liver metastases: a metaanalysis. Int J Colorectal Dis 26: 191-199.
- Hillingsø JG, Wille-Jørgensen P (2009) Staged or simultaneous resection of synchronous liver metastases from colorectal cancer--a systematic review. Colorectal Dis 11: 3-10.
- Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, et al. (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007-1016.
- Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, et al. (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the GruppoOncologico Nord Ovest. J ClinOncol 25: 1670-1676.
- Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, et al. (2008) A tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFILINOX): a phase II study in colorectal cancer patients with unresectable liver metastases. Cancer ChemotherPharmacol 62: 195-200.
- Osada S, Imai H, Sasaki Y, Tanaka Y, Okumura N, et al. (2014) Surgical Indications for Multiple and Synchronous Liver Metastases from Colorectal Cancer. Hepatogastroenterology 61: 722-726.
- de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, et al. (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250: 440-448.
- Dexiang Z, Li R, Ye W, Haifu W, Yunshi Z, et al. (2012) Outcome of patients with colorectal liver metastasis: analysis of,613 consecutive cases. Ann SurgOncol 19: 2860-2868.
- Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, et al. (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J ClinOncol 27: 1829-1835.
- Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16: 1311-1319.
- Haraldsdottir S, Wu C, Bloomston M, Goldberg RM (2013) What is the optimal neo-adjuvant treatment for liver metastasis? TherAdv Med Oncol 5: 221-234.
- Osada S, Kanematsu M, Imai H, Goshima S, Sugiyama Y (2005) Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am CollSurg 201: 405-411.
- Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, et al. (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110: 2761-2767.
- Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, et al. (2011) A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 22: 2042-2048.
- Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, et al. (2013) Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J ClinOncol 31: 1931-1938.
- Nordinger B, Van Custsem E, Gruenberger T (2009) European colorectal metastases treatment group; six international colorectal liver metastases workshop. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20: 985-990.
- Garufi C, Torsello A, Tumolo S (2010) Cetuximab plus chronomodulatedirinotecan, 5-fluoroacil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 103: 1542-1547.
- Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247: 125-135.
- Ayez N, Lalmahomed ZS, Eggermont AM, Ijzermans JN, de Jonge J, et al. (2012) Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann SurgOncol 19: 1618-1627.
- Nuzzo G, Giuliante F, Ardito F, Vellone M, Giovannini I, et al. (2008) Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. Surgery 143: 384-393.
- Karoui M, Koubaa W, Delbaldo C, Charachon A, Laurent A, et al. (2008) Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann SurgOncol 15: 3440-3446.
- Matsui S, Osada S, Tomita H, Komori S, Mori R, et al. (2010) Clinical significance of aggressive hepatectomy for colorectal liver metastasis, evaluated from the HGF/c-Met pathway. Int J Oncol 37: 289-297.
- Bates RC, Mercurio AM (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer BiolTher 4: 365-370.
- Chang HY, Kao MC, Way TD, Ho CT, Fu E (2011) Diosgenin suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition by down-regulation of Mdm2 and vimentin. J Agric Food Chem 59: 5357-5363.
- Cañadas I, Taus A, González I, Villanueva X, Gimeno J, et al. (2014) High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients. Oncotarget 5: 5246-5256.
- Ogunwobi OO, Liu C (2011) Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. ClinExp Metastasis 28: 721-731.
- Nagai T, Arao T, Furuta K (2011) Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 10: 169-177.
- Tanahashi T, Osada S, Yamada A, Kato J, Yawata K, et al. (2012) Extracellular Signal-Regulated Kinase and Akt Activation Play a Critical Role in the Process of Hepatocyte Growth Factor-Induced Epithelial-Mesenchymal Transition. Cancer: in press.
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
- Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751.
- Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, et al. (2008) Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 11: 123-151.
- Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, et al. (2010) Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 13: 109-118.
- Kajiyama H, Shibata K, Terauchi M (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31: 277-283.
- .Rho JK, Choi YJ, Lee JK (2009) Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63: 219-226.
- Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y, et al. (2011) SPARCL, Shp, MSH, E-cadherin, p, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol 17: 2028-2036.
- Koo JS, Jung W, Jeong J (2009) The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer. Jpn J ClinOncol 39: 560-568.
- Vinod BS, Antony J, Nair HH, Puliyappadamba VT, Saikia M, et al. (2013) Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. Cell Death Dis 4: e505.
- Sameshima S, Tomozawa S, Kojima M, Koketsu S, Motegi K, et al. (2008) 5-Fluorouracil-related gene expression in primary sites and hepatic metastases of colorectal carcinomas. Anticancer Res 28: 1477-1481.
- Kumamoto K, Kuwabara K, Tajima Y (2014) Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis. OncolLett 3: 983-989.
- Fukuta K, Osada S, Tanahashi T, Matsui S, Sasaki Y, et al. Increase in Chemotherapeutic Effect by Hepatocyte Growth Factor-Induced Epithelial-Mesenchymal Transition. Cancer in press.
- Levina V, Su Y, Nolen B, Liu X, Gordin Y, et al. (2008) Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 123: 2031-2040.
- Kemeny N (2007) Presurgical chemotherapy in patients being considered for liver resection. Oncologist 12: 825-839.
- Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, et al. (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247: 118-124.
- de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J ClinOncol 18: 2938-2947.
- Tournigand C, André T, Achille E, Lledo G, Flesh M, et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J ClinOncol 22: 229-237.
- White RR, Schwartz LH, Munoz JA, Raggio G, Jarnagin WR, et al. (2008) Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases. J SurgOncol 97: 601-604.
- Sasaki Y, Osada S, Mori R, Imai H, Tanaka Y, et al. (2013) Determining timing of hepatectomy for colorectal cancer with distant metastasis according to imaging-based tumor shrinkage ratio. Int J Med Sci 10: 1231-1241.
- Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, et al. (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240: 1052-1061.
- Chiappa A, Bertani E, Makuuchi M, Zbar AP, Contino G, et al. (2009) Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. Hepatogastroenterology 56: 829-834.
- Sasaki Y, Osada S, Imai H, Tanaka Y, Okumura N, et al. Tumor shrinkage direction of colorectal cancer liver metastases by chemotherapy. AntiCancer rese, in press.
- Nakanishi M, Kuriu Y, Murayama Y, Konishi H, Komatsu S, et al. (2014) Efficacy of perioperative chemotherapy in patients with colorectal cancer undergoing hepatectomy for resectable synchronous liver metastases. Hepatogastroenterol 61: 1582-1587.
- Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, et al. (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11: 38-47.
|